Search

everythinglearnresearchcommunity

for

Search:↓

A new tool can predict hair regrowth in patchy alopecia areata patients.

The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.

Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Twice-weekly 5 mg dexamethasone can effectively treat extensive alopecia areata in many patients.

Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.

Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.

DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.

Corticosteroids worked better than anthralin cream for hair regrowth.

The mixed preparation helped hair regrowth but wasn't better than minoxidil.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

UVA-1 phototherapy might help treat alopecia areata.

Candida antigen is an effective and promising treatment for alopecia areata.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.

COVID-19 infection or vaccination may influence the development of alopecia areata, a type of hair loss.

Trichoscopy is useful for diagnosing hair and scalp disorders in people with darker skin.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.

CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.

Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

People with alopecia areata often have lower vitamin D levels than healthy people.

The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.